[Evaluation of the effectiveness of prazosin in conservative treatment of benign prostatic hypertrophy].
Prazosin--a selective blocker of alpha 1-adrenergic receptors--was administered to 30 patients with benign prostatic hypertrophy. Twenty four patients (80%) reported an improvement in voiding and observed more potent urinary stream after the treatment. Average and maximum flow rates increased in 18 patients (60%). Therapy had to be discontinued in 2 patients because of the adverse reactions (hypotension and syncope in one and exacerbation of the coronary disease symptoms in another patient).
D000284:Administration, Oral; D000368:Aged; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D014554:Urination / Q000187:drug effects / Q000502:physiology; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology
D011224:Prazosin
Ocena skuteczności prazosyny w zachowawczym leczeniu łagodnego przerostu gruczołu krokowego.